CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$29.24 USD
+1.02 (3.61%)
Updated Aug 5, 2025 04:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Crinetics Pharmaceuticals, Inc. has a market cap of $2.74B, which represents its share price of $29.24 multiplied by its outstanding shares number of 93.63M. As a mid-cap company, CRNX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CRNX 29.24 +1.02(3.61%)
Will CRNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Other News for CRNX
CRNX March 2026 Options Begin Trading
JonesTrading Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News
Crinetics announces new data from its program evaluating PALSONIFY